Pacira BioSciences Inc [PCRX] stock prices are up 3.21% to $19.27 at the moment. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The PCRX shares have gain 13.96% over the last week, with a monthly amount glided 9.05%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Pacira BioSciences Inc [NASDAQ: PCRX] stock has seen the most recent analyst activity on August 13, 2024, when Truist downgraded its rating to a Sell and also revised its price target to $8 from $30. Previously, RBC Capital Mkts downgraded its rating to Sector Perform on August 12, 2024, and dropped its price target to $14. On August 12, 2024, downgrade downgraded it’s rating to Mkt Perform. Piper Sandler downgraded its rating to a Neutral and decreased its price target to $11 on August 12, 2024. JP Morgan downgraded its rating to a Underweight and reduced its price target to $10 on August 12, 2024. Barclays downgraded its rating to Equal Weight for this stock on July 03, 2024, and downed its price target to $25.
The stock price of Pacira BioSciences Inc [PCRX] has been fluctuating between $11.16 and $35.95 over the past year. Currently, Wall Street analysts expect the stock to reach $23.75 within the next 12 months. Pacira BioSciences Inc [NASDAQ: PCRX] shares were valued at $19.27 at the most recent close of the market. An investor can expect a potential return of 23.25% based on the average PCRX price forecast.
Analyzing the PCRX fundamentals
The Pacira BioSciences Inc [NASDAQ:PCRX] reported sales of 694.96M for trailing twelve months, representing a surge of 2.83%. Gross Profit Margin for this corporation currently stands at 0.68% with Operating Profit Margin at -0.09%, Pretax Profit Margin comes in at -0.08%, and Net Profit Margin reading is -0.13%. To continue investigating profitability, this company’s Return on Assets is posted at -0.06, Equity is -0.11 and Total Capital is -0.05. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.78.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 18.83 points at the first support level, and at 18.38 for the second support level. However, for the 1st resistance point, the stock is sitting at 19.56, and for the 2nd resistance point, it is at 19.84.
Ratios To Look Out For
It’s worth pointing out that Pacira BioSciences Inc [NASDAQ:PCRX]’s Current Ratio is 2.25. Also, the Quick Ratio is 1.89, while the Cash Ratio stands at 0.8. Considering the valuation of this stock, the price to sales ratio is 1.32, the price to book ratio is 1.19.
Transactions by insiders
Recent insider trading involved GAUGLER DARYL, Chief Operating Officer, that happened on Sep 13 ’24 when 500.0 shares were sold. Officer, GAUGLER DARYL completed a deal on Sep 13 ’24 to buy 500.0 shares. Meanwhile, Director BIGAL MARCELO bought 1512.0 shares on Aug 16 ’24.
